(1) It must be intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating.
(2) The condition must affect no more than 5 in 10,000 people in the EU, OR it must be unlikely that sales of the medicine will be sufficient to justify the investment needed for its development.
(3) No satisfactory method of diagnosis, prevention or treatment of the condition exists, or, if it does, the medicine in question must provide a significant benefit to those affected by the condition.
The incentives for developing orphan medicines include specific scientific advice, and 10 year market exclusivity. Market exclusivity means that no other medicine for the same condition will be granted market authorisation during this period. Reduced fees for applications for services from the EMA may also be available.